Patents by Inventor William Carroll

William Carroll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds as cannabinoid receptor ligands
    Patent number: 8735434
    Abstract: The present application relates to thiazolylidene containing compounds of formula (I) wherein R1, R2, R3, and R4 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: May 27, 2014
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Jennifer M. Frost, Sridhar Peddi
  • HEPATITIS C INHIBITORS AND USES THEREOF
    Publication number: 20140038919
    Abstract: This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
    Type: Application
    Filed: December 16, 2011
    Publication date: February 6, 2014
    Applicant: AbbVie Inc.
    Inventors: Clarence J. Maring, John K. Pratt, William A. Carroll, Dachun Liu, David A. Betebenner, Douglas K. Hutchinson, Michael D. Tufano, Todd W. Rockway, Uwe Schoen, Axel Pahl, Andreas Witte
  • Compounds as cannabinoid receptor ligands and uses thereof
    Patent number: 8546583
    Abstract: The present invention relates to compounds of formula (I), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L1 are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. The present invention also relates to compounds of formula (II), or pharmaceutical salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1a, R2a and (Rx)n are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: October 1, 2013
    Assignee: AbbVie Inc.
    Inventors: Alan S. Florjancic, Michael J. Dart, Keith B. Ryther, Arturo Perez-Medrano, William A. Carroll, Meena V. Patel, Karin Rosemarie Tietje, Tongmei Li, Teodozyj Kolasa, Megan E. Gallagher, Sridhar Peddi, Jennifer M. Frost, Derek W. Nelson
  • Amino-tetrazoles analogues and methods of use
    Patent number: 8546374
    Abstract: A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: October 1, 2013
    Assignee: Abbvie Inc.
    Inventors: William A. Carroll, Arturo Perez-Medrano, Alan S. Florjancic, Derek W. Nelson, Sridhar Peddi, Tongmei Li, Eric M. Bunnelle, Gavin Hirst, Biquin C. Li
  • ANTIGEN
    Publication number: 20130236479
    Abstract: The present invention relates to a novel method for the delivery of agents to tumour cells. In particular it relates to a method for the specific delivery of agents to the interior of tumour cells. Uses of the method are also described.
    Type: Application
    Filed: April 19, 2013
    Publication date: September 12, 2013
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Miles William Carroll, Abigail Lamikanra, Alan John Kingsman
  • Compounds as cannabinoid receptor ligands
    Patent number: 8501794
    Abstract: The present application relates to isothiazolylidene containing compounds of Formula (I) wherein R1, R2, R3, R4, and L are as defined in the specification, compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: November 4, 2009
    Date of Patent: August 6, 2013
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Teodozyj Kolasa, Tongmei Li, Derek W. Nelson, Meena V. Patel, Sridhar Peddi, Arturo Perez-Medrano, Xueqing Wang
  • Compounds as cannabinoid receptor ligands
    Patent number: 8492371
    Abstract: Disclosed herein are compounds of formula (I) wherein Ring A and R1 are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: July 23, 2013
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Jennifer M. Frost, Steven P. Latshaw, Tongmei Li, Bo Liu, Sridhar Peddi, Xueqing Wang, Teodozyj Kolasa, Derek W. Nelson, Arturo Perez-Medrano
  • Compounds as cannabinoid receptor ligands
    Patent number: 8481574
    Abstract: The present invention relates to compounds of formula (I) wherein A, E, L2, R1, R3, R4 and R5 are as defined in the herein, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: July 9, 2013
    Assignee: Abbott Laboratories
    Inventors: Michael D. Meyer, Michael J. Dart, William A. Carroll, Meena V. Patel, Tedozyi Kolasa, Xueqing Wang
  • AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE
    Publication number: 20120329772
    Abstract: A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.
    Type: Application
    Filed: July 9, 2012
    Publication date: December 27, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: William A. Carroll, Arturo Perez-Medrano, Alan S. Florjancic, Derek W. Nelson, Sridhar Peddi, Tongmei Li, Eric M. Bunnelle, Gavin Hirst, Biqin C. Li
  • Compounds as cannabinoid receptor ligands
    Patent number: 8338467
    Abstract: Disclosed herein are compounds of formula (I) wherein R1, R2, R3, R25a, R26a, X, and n are as defined in the specification. Pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions are also described.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: December 25, 2012
    Assignee: AbbVie Inc.
    Inventors: Teodozyj Kolasa, Jennifer M. Frost, Meena V. Patel, Steven P. Latshaw, Arturo Perez-Medrano, Xueqing Wang, Karin Rose Marie Tietje, Sridhar Peddi, William A. Carroll
  • Compounds as cannabinoid receptor ligands
    Patent number: 8338623
    Abstract: The present application relates to cannabinoid receptor ligands containing compounds of formula (I) wherein A, R1, R2, and R3 are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: December 25, 2012
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Derek W. Nelson
  • THROTTLING BURSTY CPU UTILIZATION DUE TO BURSTY TCP FLOWS
    Publication number: 20120278459
    Abstract: The rate of incoming data is adjusted based on processor utilization. A threshold of processor usage at which incoming data can be stopped by deferring TCP window updates can be specified. A threshold at which incoming data can be resumed by opening the TCP window can be specified. The threshold can be determined by the operating system or by a rate-adaptive video rendering application.
    Type: Application
    Filed: April 26, 2011
    Publication date: November 1, 2012
    Applicant: CISCO TECHNOLOGY, INC.
    Inventors: William Carroll VerSteeg, William E. Wall
  • Anti-Viral Compounds
    Publication number: 20120220562
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: February 24, 2012
    Publication date: August 30, 2012
    Applicant: ABBOTT LABAORATORIES
    Inventors: David A DeGoey, Warren M. Kati, Charles W. Hutchins, Pamela L. Donner, Allan C. Krueger, John T. Randolph, Sachin V. Patel, Mark A. Matulenko, Ryan G. Keddy, Tammie K. Jinkerson, Yi Gao, Dachun Liu, John K. Pratt, Todd W. Rockway, Clarence J. Maring, Douglas K. Hutchinson, Charles A. Flentge, Rolf Wagner, David A. Betebenner, Kathy Sarris, Kevin R. Woller, William A. Carroll
  • CHEMO-IMMUNOTHERAPY METHOD
    Publication number: 20120213822
    Abstract: A method of treating or preventing disease, said method comprising administering to a subject, simultaneously, sequentially or separately, an antigen and a chemotherapeutic agent or agents comprising the steps of: administering the chemotherapeutic agent or agents, and administering an antigen up to 6 weeks after the chemotherapeutic agent.
    Type: Application
    Filed: February 21, 2012
    Publication date: August 23, 2012
    Applicant: OXFORD BIOMEDICA (UK) LIMITED
    Inventors: Richard Harrop, Michelle Kelleher, William Shingler, Susan Mary Kingsman, Miles William Carroll
  • Amino-tetrazoles analogues and methods of use
    Patent number: 8217067
    Abstract: A compound having Formula (I) or Formula (II) is disclosed as an P2X7 antagonist, wherein A, B, C, Y, Y, Z, m, v, R1, R2, R3, R4, and R5, are as defined in the description. Methods and compositions for treating disease or condition modulated by P2X7 are also disclosed.
    Type: Grant
    Filed: April 29, 2005
    Date of Patent: July 10, 2012
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Arturo Perez-Medrano, Alan S. Florjancic, Derek W. Nelson, Sridhar Peddi, Tongmei Li, Eric M. Bunnelle, Gavin Hirst, Biqin C. Li
  • Anti-Viral Compounds
    Publication number: 20120172290
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: December 16, 2011
    Publication date: July 5, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: Allan C. Krueger, Warren M. Kati, William A. Carroll, John K. Pratt, Douglas K. Hutchinson
  • Compounds as cannabinoid receptor ligands
    Patent number: 8188135
    Abstract: Disclosed herein are cannabinoid receptor ligands of formula (I) wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: May 29, 2012
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Michael J. Dart, Jennifer M. Frost, Steven P. Latshaw, Teodozyj Kolasa, Tongmei Li, Sridhar Peddi, Bo Liu, Arturo Perez-Medrano, Meena Patel, Xueqing Wang, Derek W. Nelson
  • Anti-Viral Compounds
    Publication number: 20120115918
    Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
    Type: Application
    Filed: December 16, 2011
    Publication date: May 10, 2012
    Applicant: ABBOTT LABORATORIES
    Inventors: David A. DeGoey, Allan C. Krueger, Charles W. Hutchins, Warren M. Kati, William A. Carroll
  • Compounds as cannabinoid receptor ligands
    Patent number: 8173687
    Abstract: Disclosed herein are cannabinoid receptor ligands of formula (I) wherein Y, X1, X2, X3, R1, and R2 are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: May 8, 2012
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Michael J. Dart, Jennifer M. Frost, Teodozyj Kolasa, Steven P. Latshaw, Bo Liu, Meena V. Patel, Arturo Perez-Medrano, Xueqing Wang
  • Compounds as cannabinoid receptor ligands and uses thereof
    Patent number: 8158663
    Abstract: The present invention relates to thiazolidinylidene containing compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, and X are as defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: April 17, 2012
    Assignee: Abbott Laboratories
    Inventors: William A. Carroll, Michael J. Dart, Tongmei Li, Arturo Perez-Medrano, Sridhar Peddi